Vertex Wins FDA Approval for Casgevy in Children as Young as 2

LONDON, Sunday, July 5, 2026 — The U.S. Food and Drug Administration approved Vertex Pharmaceuticals' CRISPR gene therapy Casgevy for children as young as 2 on July 1, adding roughly 5,500 eligible U.S. patients to its market. The agency called it the first gene therapy cleared for patients aged 2 and older with sickle cell disease. Vertex said the decision covers both severe sickle cell disease and transfusion-dependent beta thalassemia. The therapy carries a $2.2 million list price, unchanged since its 2023 launch.

Key Takeaways

• The FDA cleared Casgevy for children aged 2 and older, expanding the eligible U.S. population by roughly 5,500 patients.
• The approval came 53 days after filing, the eighth under the FDA's Commissioner's National Priority Voucher pilot.
• Casgevy generated $116 million in 2025 revenue from 64 infused patients, according to company disclosures — underscoring an uptake challenge the pediatric label aims to ease.
• Vertex faces looming competition from Beam Therapeutics' base-editing candidate and rebranded rival Genetix (formerly Bluebird Bio).

Context & Analysis

Casgevy edits a patient's own blood stem cells using CRISPR/Cas9 at the BCL11A gene, restoring fetal hemoglobin production. Vertex co-developed the therapy with CRISPR Therapeutics, and it became the first approved CRISPR medicine when the FDA cleared it for patients 12 and older in December 2023.

The pediatric expansion rests on trials in younger children. Among eight efficacy-evaluable sickle cell patients (out of 11 enrolled) aged 5 to less than 12, all achieved the primary endpoint of no severe pain crises for 12 consecutive months. The FDA extrapolated to ages 2 to 4.

For deeper context, see our related analysis: "Genetics market size surges amid sequencing boom and therapy wins".

Competitive Landscape

Rivalry is intensifying. Bluebird Bio was acquired by Carlyle and SK Capital Partners in a deal completed in June 2025, after the firms raised their offer to $5.00 per share (from an initial $3.00), plus a contingent value right of up to $6.84 per share in early 2025 and rebranded as Genetix, Bluebird reported 74 patient starts across its three gene therapies (including Lyfgenia, Zynteglo and Skysona) by the end of 2024, with 17 of those starts for Lyfgenia as of November 2024. Genetix reportedly aims to treat 1,000 patients per year by 2030, according to the Boston Globe, while Beam Therapeutics may win approval next year for a gentler base-editing therapy that could be easier to manufacture.

Related: How Health Tech Is Unifying Clinical Data in 2026, According to Deloitte and Gartner

Related: Genetics Innovation Hits an Inflection Point as Editing Moves From Lab to Market

Why It Matters

For Enterprise Buyers

Health systems and payers face a scaling test. Between 50 and 60 percent of the roughly 100,000 Americans with sickle cell are on Medicaid, straining state budgets facing million-dollar one-time therapies. Vertex has more than 75 authorized treatment centers, but access remains geographically concentrated.

For deeper context, see our Health Tech analysis: "Pathway Labs Gains FDA Clearance for AI Heart Tool".

For Investors

Casgevy sales fell to $42.9 million in Q1 2026 from $54.3 million in Q4 2025, reflecting infusion variability. Vertex believes the therapy holds multibillion-dollar potential if uptake ramps. The pediatric market widens the runway but does not resolve the delivery bottleneck.

What Happens Next

Vertex has completed regulatory submissions in Saudi Arabia and the United Kingdom to expand Casgevy to children as young as five. The company expects Casgevy and its pain drug Journavx to combine for $500 million in 2026, a 185% jump over 2025. Investors will watch treatment volumes across authorized centers and long-term safety data from the youngest cohorts.

Additional coverage: Hims & Hers: $1.15B Eucalyptus Deal Closes, Adds 850K Customers

Additional coverage: Genetics by the Numbers: Costs Fall as Clinical Use Accelerates

FAQ

What did the FDA approve on July 1, 2026?

The FDA approved expanded use of Vertex's Casgevy for patients aged 2 and older with sickle cell disease with recurrent vaso-occlusive crises or transfusion-dependent beta thalassemia. It was previously limited to patients 12 and older.

Related: Siemens Healthineers and GE HealthCare Advance AI Imaging Adoption

How many additional patients are now eligible?

Vertex estimates approximately 5,500 additional children in the U.S. are now eligible for the one-time therapy.

How much does Casgevy cost?

Casgevy carries a $2.2 million list price, unchanged since its original 2023 approval. Roughly half of U.S. sickle cell patients are covered by Medicaid, raising access concerns.

For deeper context, see our Robotics analysis: "Stendr Raises $5.4M for AI Drone Defence Tech in Nordic 2026".

Who competes with Vertex in this market?

Genetix (formerly Bluebird Bio) markets the rival lentiviral therapy Lyfgenia, and Beam Therapeutics is advancing a base-editing candidate that could reach the market in 2027.

Why has Casgevy uptake been slow?

Only 64 patients globally received Casgevy in 2025. The therapy requires apheresis, myeloablative chemotherapy, and weeks of inpatient care at specialized centers, alongside the high price and reimbursement complexity.

Sources include company disclosures, regulatory filings, analyst reports, and industry briefings.

Related Coverage

• More Health Tech Analysis
• Latest Technology News

Analysis based on company announcements, investor disclosures, regulatory filings, Reuters, Bloomberg, Financial Times, CNBC, SEC documentation, and publicly available market data as of publication.